Welcome, sign in or click here to subscribe.
Login: Password:




Email to a friend   Print   Comment   Reprints   Add to myDJC   Adjust font size

January 3, 2018


In Seattle, OncoResponse added Anil Singhal, Ph.D., as chief scientific officer, and Kamal D. Puri, Ph.D., as vice president of research and development. Singhal comes from AbbVie, and Puri from Celgene. Houston-based OncoResponse develops therapeutic antibodies for cancer patients.